Necrostatin‐1 releasing nanoparticles: In vitro and in vivo efficacy for supporting immunoisolated islet transplantation outcomes

Abstract

AbstractImmunoisolation of pancreatic islets in alginate microcapsules allows for transplantation in the absence of immunosuppression but graft survival time is still limited. This limited graft survival is caused by a combination of tissue responses to the encapsulating biomaterial and islets. A significant loss of islet cells occurs in the immediate period after transplantation and is caused by a high susceptibility of islet cells to inflammatory stress during this period. Here we investigated whether necrostatin‐1 (Nec‐1), a necroptosis inhibitor, can reduce the loss of islet cells under stress in vitro and in vivo. To this end, we developed a Nec‐1 controlled‐release system using poly (D,L‐lactide‐co‐glycolide) (PLGA) nanoparticles (NPs) as the application of Nec‐1 in vivo is limited by low stability and possible side effects. The PLGA NPs stably released Nec‐1 for 6 days in vitro and protected beta cells against hypoxia‐induced cell death in vitro. Treatment with these Nec‐1 NPs at days 0, 6, and 12 post‐islet transplantation in streptozotocin‐diabetic mice confirmed the absence of side effects as graft survival was similar in encapsulated islet grafts in the absence and presence of Nec‐1. However, we found no further prolongation of graft survival of encapsulated grafts which might be explained by the high biocompatibility of the alginate encapsulation system that provoked a very mild tissue response. We expect that the Nec‐1‐releasing NPs could find application to immunoisolation systems that elicit stronger inflammatory responses, such as macrodevices and vasculogenic biomaterials.